Cargando…

Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants

Blocking androgen receptor (AR) transcriptional activity by androgen deprivation therapy (ADT) improves the response to radiotherapy for intermediate and high risk prostate cancer. Unfortunately, ADT, antiandrogens, and abiraterone increase expression of constitutively active splice variants of AR (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banuelos, Carmen A., Ito, Yusuke, Obst, Jon K., Mawji, Nasrin R., Wang, Jun, Hirayama, Yukiyoshi, Leung, Jacky K., Tam, Teresa, Tien, Amy H., Andersen, Raymond J., Sadar, Marianne D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409302/ https://www.ncbi.nlm.nih.gov/pubmed/32708219 http://dx.doi.org/10.3390/cancers12071991

Ejemplares similares

Pin1 inhibition improves the efficacy of ralaniten compounds that bind to the N-terminal domain of androgen receptor
por: Leung, Jacky K., et al.
Publicado: (2021)

Differential Gene Expression Profiles between N-Terminal Domain and Ligand-Binding Domain Inhibitors of Androgen Receptor Reveal Ralaniten Induction of Metallothionein by a Mechanism Dependent on MTF1
por: Obst, Jon K., et al.
Publicado: (2022)

Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Ralaniten Analogs for the Treatment of Androgen Receptor–positive Prostate and Breast Cancers
por: Tien, Amy H., et al.
Publicado: (2022)

Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer
por: Hirayama, Yukiyoshi, et al.
Publicado: (2020)

Non-Genomic Actions of the Androgen Receptor in Prostate Cancer
por: Leung, Jacky K., et al.
Publicado: (2017)

Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy
por: Shimizu, Yasuomi, et al.
Publicado: (2018)

Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer
por: Myung, Jae-Kyung, et al.
Publicado: (2017)

Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
por: Ito, Yusuke, et al.
Publicado: (2018)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

SAT022 A Mechanism Of Resistance To Novel Inhibitors Of The N-Terminal Domain Of Androgen Receptor
por: Setiawan, Josie, et al.
Publicado: (2023)

Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer
por: Ware, Kathryn E., et al.
Publicado: (2016)

Characterization of Niphatenones that Inhibit Androgen Receptor N-Terminal Domain
por: Banuelos, Carmen A., et al.
Publicado: (2014)

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
por: Chou, Fu-Ju, et al.
Publicado: (2020)

Splice Variants of Androgen Receptor and Prostate Cancer
por: Caffo, Orazio, et al.
Publicado: (2016)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
por: Khurana, Namrata, et al.
Publicado: (2020)

Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
por: Imamura, Yusuke, et al.
Publicado: (2016)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Molecular mechanisms of enzalutamide resistance in prostate cancer
por: Blatt, Eliot B., et al.
Publicado: (2019)

Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer
por: Detert Oude Weme, S. E. H., et al.
Publicado: (2023)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

FUS/TLS Is a Co-Activator of Androgen Receptor in Prostate Cancer Cells
por: Haile, Simon, et al.
Publicado: (2011)

SAT023 The Role Of Cysteine Residues In The Binding Of Inhibitors Of The N-Terminal Domain Of The Androgen Receptor
por: Deneault, Lauren, et al.
Publicado: (2023)

Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance
por: Nicolescu, Radu Costin Bizga, et al.
Publicado: (2022)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer
por: Vander Ark, Alexandra, et al.
Publicado: (2018)

Molecular determinants for enzalutamide-induced transcription in prostate cancer
por: Yuan, Fuwen, et al.
Publicado: (2019)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
por: Lopes, Nair, et al.
Publicado: (2021)

Role of androgen receptor splice variants in prostate cancer metastasis
por: Xu, Jin, et al.
Publicado: (2016)

Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
por: Salami, Jemilat, et al.
Publicado: (2018)

Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer
por: Zhao, Jingwen, et al.
Publicado: (2016)

The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression()
por: Li, Zhenghong, et al.
Publicado: (2020)

Androgen Receptor Blockade Using Enzalutamide Suppresses Long Non-Coding RNA ARLNC1 in Prostate Cancer Cells
por: Huseynova, Günel, et al.
Publicado: (2022)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Enzalutamide: A New Agent for the Prostate Cancer Treatment Armamentarium
por: McCutcheon, Stephanie B.
Publicado: (2013)

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
por: Linder, Simon, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u180q8ufhcdrj10fotgdc73uqm